Know Cancer

forgot password

A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3
18 Years
Not Enrolling
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive

- One (1) unidimensionally measurable lesion

- ECOG Performance Status of 0 or 1, no peripheral neuropathy >Grade 1

- Patients with clinically stable brain metastases on a stable dose of (or no longer
requiring) dexamethasone at registration will be eligible. Patients who have received
cranial radiation for brain metastases must be at least 4 weeks from last radiation

- Recovery in full from any previous surgical procedure

- No history of an acute cardiac or CNS event within 6 months of entry or current
clinical evidence of congestive heart failure or non-stable coronary artery disease

Exclusion Criteria:

- Hypersensitivity to any of the 4 study drugs

- Concurrent immunotherapy or participation in any investigational drug study within 4

- Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft

- History of other malignancy within the last 5 years (except for squamous or basal
cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial
transitional cell carcinoma of the bladder)

- Patient is a pregnant or lactating female

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the relative efficacy, safety and clinical benefit of the GEMOX regimen compared to the standard combination regimen of CP as first-line treatment of Stage IIIB and IV NSCLC

Outcome Time Frame:

22 months

Principal Investigator

Yasir Nagarwala, MD

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

March 2004

Completion Date:

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Texas Oncology, P.A. Dallas, Texas  75246
Virginia Oncology Associates Newport News, Virginia  23606
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Ocala Oncology Center Ocala, Florida  34474
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Missouri Cancer Associates Columbia, Missouri  65201
Rocky Mountain Cancer Centers Thornton, Colorado  80260
New Mexico Cancer Care Associates Santa Fe, New Mexico  87505-7670
Tyler Cancer Center Tyler, Texas  75702
Cancer Care Northwest Spokane, Washington  99202
Berkshire Hematology Oncology, PC Pittsfield, Massachusetts  01201
Oncology Associates of Cedar Rapids Cedar Rapids, Iowa  52403
Cancer Care Associates Tulsa, Oklahoma  74136
Willamette Valley Cancer Center Eugene, Oregon  97401-8122
San Antonio Tumor and Blood Clinic San Antonio, Texas  78217
New York Oncology Hematology, P.C. Albany, New York  12208
Hematology Oncology Associates of Illinois Skokie, Illinois  60077
Interlakes Oncology & Hematology, P.C. Rochester, New York  14623
Cancer Centers of Florida, P.A. Orlando, Florida  
Raleigh Hematology Oncology Clinic Cary, North Carolina  27511
Florida Cancer Institute New Port Richey, Florida  34652
South Florida Oncology & Hematology Consultants Plantation, Florida  33324
Central Indiana Cancer Centers Indianapolis, Indiana  46227
Minnesota Oncology Hematology, P.A. Minneapolis, Minnesota  55407
Texas Cancer Center at Medical City Dallas, Texas  75230
Allison Cancer Center Midland, Texas  79701
West Texas Cancer Center Odessa, Texas  79761
New York Oncology Hematology Albany, New York  12208
Hematology Oncology Associates Phoenix, Arizona  85012
Arch Medical Services, INC. St. Louis, Missouri  63142
Northwest Cancer Specialists, P.C. Vancouver, Washington  
Texas Oncology Cancer Center Austin, Texas  78731
Mamie McFaddin Ward Cancer Center Beaumont, Texas  77702
The Texas Cancer Center Dallas, Texas  75237
Lake Vista Cancer Center Lewisville, Texas  75067
Longview Cancer Center Longview, Texas  75601
Texas Cancer Center of Mesquite Mesquite, Texas  75150
Hematology Oncology Associates of South Texas San Antonio, Texas  78229
Kansas City Oncology and Hematology Group Kansas City, Kansas  66112
Birmingham Hematology and Oncology Associates, LLC Birmingham, Alabama  35235
Northern Arizona Hematology & Oncology Associates Sedona, Arizona  86336
Northwest Medical Specialists, PC Niles, Illinois  60714
Deke Slayton Cancer Center Webster, Texas  77589
Puget Sound Cancer Centers Edmonds, Washington  98026
Birmingham Hematology and Oncology Associates Birmingham, Alabama  35235
Arizona Oncology Associates - Hematology Oncology Physicians Tucson, Arizona  85704
Maryland Oncology Hematology, P.A. Columbia, Maryland  21044
Minnesota Oncology Hematology Minneapolis, Minnesota  55404
Piedmont Hematology Oncology Associates, PLLC. Winston-Salem, North Carolina  27103
Dayton Oncology & Hematology, P.A. Kettering, Ohio  45409
Texas Cancer Center - Abilene Abilene, Texas  79606
Texas Cancer Center - Denton Denton, Texas  76210
El Paso Cancer Treatment Ctr-East El Paso, Texas  79915
South Texas Cancer Center - McAllen McAllen, Texas  78503-1298
Paris Regional Cancer Center Paris, Texas  75460
Texas Cancer Center - Sherman Sherman, Texas  75090-0504
Waco Cancer Care and Research Center Waco, Texas  76712
Fairfax Northern Virginia Hematology Oncology, PC Fairfax, Virginia  22031
Oncology & Hematology Associates of Southwest Virginia, Inc. Salem, Virginia  24153